Abstract
The efficacy of mometasone furoate for children with asthma: a meta-analysis of randomized controlled trials
- Department of Paediatrics, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China
- Department of Paediatrics, The First People’s Hospital of Xiaoshan, Hangzhou, Zhejiang Province, China
Introduction
The influence of mometasone furoate for paediatric asthma remains controversial.
Aim
We conducted a systematic review and meta-analysis to explore the efficacy and safety of mometasone furoate for paediatric asthma.
Material and methods
We have searched PubMed, Embase, Web of science, EBSCO, and Cochrane library databases through October 2019 for randomized controlled trials assessing the effect of mometasone furoate versus placebo for paediatric asthma. This meta-analysis was performed using the random-effects model.
Results
Four RCTs were included in the meta-analysis. Overall, as compared to placebo for paediatric asthma, mometasone furoate is associated with substantially increased predicted forced expiratory volume in 1 s (FEV1) (mean difference (MD) = 7.53; 95% CI: 7.02–8.04; p < 0.00001), FEV1 (MD = 0.11; 95% CI: 0.10–0.12; p < 0.00001), and morning peak expiratory flow (AM PEF) (MD = 17.70; 95% CI: 9.91–25.49; p < 0.00001), but demonstrates no obvious effect on pharyngitis (RR = 0.96; 95% CI: 0.59–1.58; p = 0.89), upper respiratory tract infections (RR = 0.73; 95% CI: 0.50–1.05; p = 0.09), or adverse events (RR = 1.05; 95% CI: 0.84–1.31; p = 0.69).
Conclusions
Mometasone furoate may be effective and safe for paediatric asthma.
Keywords
mometasone furoate, paediatric asthma, forced expiratory volume in 1 s, randomized controlled trials
Indexed in
Integrated with
